Bloodstream infections are a leading cause of sepsis, a dysregulated immune response leading to systemic inflammation, organ failure and death, with substantial global morbidity and mortality. Rapid identification of causative pathogens and early treatment are crucial for patient survival, while delayed therapeutic intervention or inappropriate initial therapy worsen clinical outcomes and increase the risk of mortality.
Mutations associated with autism spectrum disorder (ASD) alter the physical interactions between proteins. To understand how these changes affect brain development, scientists at the University of California San Francisco (UCSF) have generated the largest ASD protein interaction map to date and validated their findings in brain organoids.
Bloodstream infections are a leading cause of sepsis, a dysregulated immune response leading to systemic inflammation, organ failure and death, with substantial global morbidity and mortality. Rapid identification of causative pathogens and early treatment are crucial for patient survival, while delayed therapeutic intervention or inappropriate initial therapy worsen clinical outcomes and increase the risk of mortality.
Mutations associated with autism spectrum disorder (ASD) alter the physical interactions between proteins. To understand how these changes affect brain development, scientists at the University of California San Francisco (UCSF) have generated the largest ASD protein interaction map to date and validated their findings in brain organoids.
Adicet Bio Inc. has obtained clearance from the U.S. FDA for its IND application for ADI-212 for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).
Profound Therapeutics Inc. has received an investment commitment of up to $35 million from the Gates Foundation, including an initial investment of $20 million, to create new solutions for women’s health.
Dana-Farber Cancer Institute Inc. has patented proteolysis targeting chimera (PROTAC) compounds consisting of a E3 ubiquitin-protein ligase Mdm2-binding moiety covalently linked to cyclin-dependent kinase 9 (CDK9)-targeting moieity reported to be useful for the treatment of cancer.
CSPC Pharmaceutical Group Ltd. has obtained approval from the National Medical Products Administration of the People’s Republic of China to conduct clinical trials of its SYH-2092 injection in China (NCT07776041).
Histone acetyltransferase KAT6A is a modulator of gene expression in cancer and hematopoietic cells, thus being an epigenetic target in cancer therapy. KAT6A inhibitors are used in breast cancer therapy, but some of them such as prifetrastat are associated with on-target toxicity including...
Shy Therapeutics LLC has developed and presented data for SHY-ONC6, a novel inhibitor of the proteasome 19S regulator particle (RP) ATPases for the potential treatment of hematological malignancies such as multiple myeloma and mantle-cell lymphoma, as well as solid tumors.
The scientific community continues to make progress at uncovering the elements that could lead to a cure for HIV. The virus remains latent in reservoirs that are difficult to eliminate, so researchers are pursuing two main strategies. The “shock-and-kill” approach aims to wake up latent virus and...
University of Miami and Starx Therapeutics Inc. have presented data on UMF-814A, a STK17A inhibitor with promising activity in myelodysplastic syndrome and acute myeloid leukemia.
Cancer-associated fibroblasts (CAFs) are a major component of the tumor microenvironment in fibrotic breast cancer, especially the myofibroblastic subtype (myCAFs), which forms a dense extracellular matrix that limits immune cell penetration and promotes immunosuppression. Rather than depleting...
Minapharm Group will receive up to $16.5 million from the Coalition for Epidemic Preparedness Innovations (CEPI) to advance the development of a Bundibugyo ebolavirus vaccine candidate, as part of efforts to develop vaccines to combat the fastest-growing and second-largest Ebola outbreak on record...
Researchers from Ocean University of China reported the design and preclinical characterization of CHNQD-02204, a flavone derivative with antifungal activity.
Scientists from the Massachusetts Institute of Technology, The Brigham and Women’s Hospital Inc. and The Broad Institute Inc. have divulged drug conjugates (complement recruiting chimeric) consisting of a pathogen binding moiety and a protein C3 chimera molecule through a linker reported to be...
Recent research indicates that pharmacological inhibition of poly(ADP-ribose) polymerase 7 (PARP7) mitigates post-stroke inflammation by modulating type I interferon and other inflammatory signaling pathways, thereby reducing ischemic brain injury and promoting neurological recovery. Chinese...
In drug discovery, human genetics are considered a strong indicator of potential success for a target. That belief, though, has not yet translated into robust drug discovery efforts for the strongest genetic risk factor ever to come out of a GWAS: ApoE in Alzheimer’s disease.
CD300c is an activating myeloid-cell receptor implicated in monocyte-to-macrophage differentiation, making it a potential therapeutic target in Alzheimer’s disease (AD) through the promotion of amyloid-β clearance and modulation of disease-associated neuroinflammation. Researchers from Centricsbio...
Chengdu Mfs Pharma Co. Ltd. has divulged ketone heterocyclic compounds potentially useful for the treatment of pain, sleep disorder, and status epilepticus epilepsy and useful as anesthetics.
Revier Therapeutics GmbH has reported the closing of a €6 million (US$7 million) seed financing and the launch of its operations. The company has established the first therapeutic approach to selectively target class IIa histone deacetylases (HDACs) for the treatment of cardiometabolic diseases.
Researchers have recently published data regarding miR-34a-5p, a microRNA that usually shows decreased expression in cancer associated with treatment resistance. The involvement of miR-34a-5p in radioresistance in esophageal adenocarcinoma is not well defined.
Respiratory syncytial virus (RSV) infection is responsible for 3.2 million hospital admissions and about 118,000 deaths in children under 5 years of age. The increased risk of RSV infection (and other infectious diseases) in young children is broadly attributed to their immature immune system. But...
In a recent study, researchers from Washington University School of Medicine and collaborators analyzed cross-sectional blood samples to identify circRNAs associated with Alzheimer’s disease (AD) clinical status, amyloid-β and tau stages, and progression to symptomatic AD.
Death receptor 3 (DR3) plays a central role in the pathogenesis of inflammatory bowel disease (IBD) through its interaction with the cytokine TL1A. Researchers from Shattuck Labs Inc. reported the preclinical characterization of SL-325, a...
Shanghai Longke Pharmaceutical Co. Ltd. has disclosed 17-β-hydroxysteroid dehydrogenase 13 (HSD17B13; 17-β-HSD 13) inhibitors reported to be useful for the treatment of liver diseases.
A compound targeting serotonin receptor 5-HT2A (5-HT2AR) signaling in the gut could activate antitumor immunity in colorectal cancer (CRC) and improve responses to immunotherapy without causing psychedelic effects in the brain. The activation of...
Chronic liver injury promotes hepatic fibrosis through the activation of hepatic stellate cells and excessive extracellular matrix deposition, a process that can progress to cirrhosis and liver cancer. Researchers from Xiamen University used...
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological imprint. At the 26th International AIDS Conference (AIDS 2026), researchers reported...
Chinese researchers have reported the discovery and preclinical characterization of a series of novel ibuprofen derivatives designed to modulate MAPK signaling and restore intestinal immune homeostasis.
Understand the present and future of drug and medical technology innovation with our premium videos and podcasts, produced for biotechnology, pharmaceutical and healthcare technology professionals. Featuring exclusive interviews with industry pioneers, executives, regulatory experts and leading researchers, our multimedia content translates complex news into actionable insights shaping the future of patient care.
Understand the present and future of drug and medical technology innovation with our premium videos and podcasts, produced for biotechnology, pharmaceutical and healthcare technology professionals. Featuring exclusive interviews with industry pioneers, executives, regulatory experts and leading researchers, our multimedia content translates complex news into actionable insights shaping the future of patient care.